Stifel Sticks With Buy on REGENXBIO Amid Clinical Hold, Cites $45 Target
Stifel has reaffirmed a Buy rating and a $45.00 price target on REGENXBIO Inc. (RGNX) even after the Food and Drug Administration placed clinical holds on RGX-111 and RGX-121. The firm expects delays to the RGX-121 PDUFA timing but says other programs remain insulated and highlights the company’s response efforts and manufacturing differences betwe…